Briacell Therap (NASDAQ:BCTX) Announces Quarterly Earnings Results

Briacell Therap (NASDAQ:BCTX) issued its quarterly earnings results on Wednesday. The company reported ($1.50) earnings per share (EPS) for the quarter, FiscalAI reports.

Briacell Therap Stock Down 1.7%

NASDAQ BCTX traded down $0.06 on Wednesday, reaching $3.50. The company had a trading volume of 42,665 shares, compared to its average volume of 303,587. Briacell Therap has a 12 month low of $2.60 and a 12 month high of $13.43. The firm’s 50 day moving average price is $3.80 and its 200 day moving average price is $3.91. The stock has a market capitalization of $30.45 million, a PE ratio of -0.44 and a beta of 1.21.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Briacell Therap in a research note on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Briacell Therap presently has an average rating of “Sell”.

Briacell Therap Company Profile

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. Its research is centered on treatments designed to stimulate a patient’s immune system to recognize and attack tumor cells, with an emphasis on advanced breast cancer and other solid tumors.

The company’s lead technology includes Bria-IMT, an off-the-shelf, whole-cell immunotherapy derived from a breast cancer cell line. BriaCell has also been developing Bria-OTS, a personalized immunotherapy approach intended to match treatment with a patient’s human leukocyte antigen profile.